$MAIA
MAIA Biotechnology, Inc.

2023 Q2 Form 10-Q Financial Statement

#000095017023018480 Filed on May 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.065M $1.988M $1.366M
YoY Change 56.16% 45.53% 73.39%
% of Gross Profit
Research & Development $2.599M $2.196M $2.077M
YoY Change 22.64% 5.71% 690.58%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $4.665M $4.184M $3.444M
YoY Change 120.09% 21.51% 227.74%
Operating Profit -$4.665M -$4.184M -$3.444M
YoY Change 35.52% 21.51%
Interest Expense $1.715K $5.147K $470.00
YoY Change 1549.04% 995.11% -100.61%
% of Operating Profit
Other Income/Expense, Net $142.6K $72.19K $29.24K
YoY Change 4.95% 146.89% -72.63%
Pretax Income -$4.524M -$4.117M -$3.414M
YoY Change 36.84% 20.59% 234.19%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$4.524M -$4.117M -$3.414M
YoY Change 36.84% 20.59% 234.19%
Net Earnings / Revenue
Basic Earnings Per Share -$0.35 -$0.38 -$0.50
Diluted Earnings Per Share -$0.35 -$0.38 -$321.0K
COMMON SHARES
Basic Shares Outstanding 13.63M 11.00M 7.752M
Diluted Shares Outstanding 12.89M 10.98M 7.752M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.146M $7.586M $10.29M
YoY Change 12.22% -26.3%
Cash & Equivalents $0.00 $0.00 $10.29M
Short-Term Investments
Other Short-Term Assets $243.3K $398.9K $234.6K
YoY Change -5.12% 70.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $9.776M $8.334M $10.53M
YoY Change 13.55% -20.84%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.800K $2.800K $916.5K
YoY Change 0.0% -99.69%
Total Long-Term Assets $492.4K $740.5K $916.5K
YoY Change -57.18% -19.2%
TOTAL ASSETS
Total Short-Term Assets $9.776M $8.334M $10.53M
Total Long-Term Assets $492.4K $740.5K $916.5K
Total Assets $10.27M $9.074M $11.44M
YoY Change 5.22% -20.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.549M $1.127M $895.1K
YoY Change 48.73% 25.95%
Accrued Expenses $1.724M $2.639M $1.421M
YoY Change -16.16% 85.66%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $3.273M $3.766M $2.431M
YoY Change 5.66% 54.94%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $121.6K $224.4K
YoY Change
Total Long-Term Liabilities $121.6K $224.4K $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.273M $3.766M $2.431M
Total Long-Term Liabilities $121.6K $224.4K $0.00
Total Liabilities $3.394M $3.991M $2.431M
YoY Change 9.58% 64.17%
SHAREHOLDERS EQUITY
Retained Earnings -$52.85M -$48.32M
YoY Change 50.32%
Common Stock $1.365K $1.100K
YoY Change 62.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $6.874M $5.083M $9.014M
YoY Change
Total Liabilities & Shareholders Equity $10.27M $9.074M $11.44M
YoY Change 5.22% -20.71%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$4.524M -$4.117M -$3.414M
YoY Change 36.84% 20.59% 234.19%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$2.561M -$3.361M -$2.546M
YoY Change 12.23% 32.01% 904.94%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $2.374M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.120M 0.000 2.269M
YoY Change 2803.93% -100.0% -6.6%
NET CHANGE
Cash From Operating Activities -2.561M -3.361M -2.546M
Cash From Investing Activities
Cash From Financing Activities 4.120M 0.000 2.269M
Net Change In Cash 1.559M -3.365M -276.6K
YoY Change -172.86% 1116.64% -112.71%
FREE CASH FLOW
Cash From Operating Activities -$2.561M -$3.361M -$2.546M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001878313
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-41455
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
MAIA BIOTECHNOLOGY, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-1495913
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
444 West Lake Street
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1700
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Chicago
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
IL
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
60606
CY2023Q1 dei City Area Code
CityAreaCode
312
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
416-8592
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2023Q1 dei Trading Symbol
TradingSymbol
MAIA
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NYSE
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
13625925
CY2023Q1 us-gaap Cash
Cash
7586312
CY2022Q4 us-gaap Cash
Cash
10950927
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
398874
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
554321
CY2023Q1 maia Research And Development Incentives Receivable
ResearchAndDevelopmentIncentivesReceivable
348379
CY2022Q4 maia Research And Development Incentives Receivable
ResearchAndDevelopmentIncentivesReceivable
302789
CY2023Q1 us-gaap Assets Current
AssetsCurrent
8333565
CY2022Q4 us-gaap Assets Current
AssetsCurrent
11808037
CY2023Q1 us-gaap Deferred Costs
DeferredCosts
737688
CY2022Q4 us-gaap Deferred Costs
DeferredCosts
211203
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2800
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2800
CY2023Q1 us-gaap Assets
Assets
9074053
CY2022Q4 us-gaap Assets
Assets
12022040
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1127412
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1165505
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2639034
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2103401
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
3766446
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3268906
CY2023Q1 maia Warrant Liability Noncurrent
WarrantLiabilityNoncurrent
224399
CY2022Q4 maia Warrant Liability Noncurrent
WarrantLiabilityNoncurrent
245341
CY2023Q1 us-gaap Liabilities
Liabilities
3990845
CY2022Q4 us-gaap Liabilities
Liabilities
3514247
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
70000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
70000000
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10996404
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10996404
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10955904
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10955904
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
1100
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1096
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
164070
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
53431530
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
52729942
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-48324148
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-44207272
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-25274
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-15973
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
5083208
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
8507793
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9074053
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12022040
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2195991
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2077329
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1988259
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1366229
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
4184250
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
3443558
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4184250
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3443558
CY2023Q1 us-gaap Interest Expense
InterestExpense
5147
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
336
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
472
CY2023Q1 maia Australian Research And Development Incentives
AustralianResearchAndDevelopmentIncentives
51243
CY2022Q1 maia Australian Research And Development Incentives
AustralianResearchAndDevelopmentIncentives
29241
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-20942
CY2023Q1 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
67374
CY2022Q1 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
29713
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-4116876
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-3413845
CY2022Q1 maia Deemed Dividend On Warrant Modification
DeemedDividendOnWarrantModification
-450578
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4116876
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3864423
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.38
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.38
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.50
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.50
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10977054
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10977054
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7752042
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7752042
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4116876
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3864423
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-9301
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
1721
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4126177
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3862702
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
8507793
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
537522
CY2023Q1 maia Foreign Currency Translation Adjustment
ForeignCurrencyTranslationAdjustment
-9301
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-4116876
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
5083208
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9181203
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
47700
CY2022Q1 maia Issuance Of Common Shares Upon Exercise Of Warrants
IssuanceOfCommonSharesUponExerciseOfWarrants
110000
CY2022Q1 maia Issuance Of Common Shares In Connection With Equity Financing
IssuanceOfCommonSharesInConnectionWithEquityFinancing
2373561
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
713330
CY2022Q1 maia Foreign Currency Translation Adjustment
ForeignCurrencyTranslationAdjustment
1721
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-3413845
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9013670
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-4116876
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-3413845
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
537522
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
713330
CY2023Q1 maia Consulting Expense For Restricted Shares Issued
ConsultingExpenseForRestrictedSharesIssued
164070
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-20942
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-153775
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
134341
CY2023Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
51243
CY2022Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-322
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-35163
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-67120
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
534693
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
352874
CY2023Q1 maia Increase Decrease In Deferred Offering Cost
IncreaseDecreaseInDeferredOfferingCost
526485
CY2022Q1 maia Increase Decrease In Deferred Offering Cost
IncreaseDecreaseInDeferredOfferingCost
262093
CY2022Q1 us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
3062
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3360649
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2807811
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2373561
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
47700
CY2022Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
110000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2531261
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-3966
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-4282
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3364615
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-280832
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10950927
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10574292
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7586312
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10293460
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2018-08-03
CY2023Q1 us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
minority stockholder of THIO received one share of MAIA common stock for each share of THIO common stock owned prior to the merger.
CY2023Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
1
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-48324148
CY2023Q1 us-gaap Cash
Cash
7586312
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6545628
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.55
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of the Company’s unaudited interim condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The most significant estimates in the Company’s financial statements relate to the valuation of common stock, stock options and warrants, the embedded features in convertible notes, and accruals for outsourced research and development activities. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</span></p>
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M2D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
672287
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.08
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7217915
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.69
CY2023Q1 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1409860
CY2022Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1094582
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
709454
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
332589
CY2023Q1 maia Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
357469
CY2022Q4 maia Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
516961
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
162251
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
159269
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2639034
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2103401
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
70000000
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2373561
CY2022Q1 maia Transaction Costs
TransactionCosts
0
CY2022Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
99999
CY2022Q2 maia Transaction Costs
TransactionCosts
0
CY2022Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
9.00
CY2022Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9093830
CY2022Q2 maia Warrants Exercised Shares
WarrantsExercisedShares
394501
CY2022Q2 maia Cashless Exercise At Fair Market Value Per Share
CashlessExerciseAtFairMarketValuePerShare
9
CY2022Q2 maia Issuance Of Common Shares Upon Cashless Exercise Of Warrants Shares
IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares
315601
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.25
CY2022Q3 us-gaap Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable
ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
2023-01-23
CY2022Q3 maia Class Of Warrant Or Right Date From Which Warrants Or Rights Expire
ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire
2027-07-27
CY2023Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
224399
CY2022Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
245341
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
796985
CY2022Q4 maia Class Of Warrants Weighted Average Exercise Price
ClassOfWarrantsWeightedAverageExercisePrice
6.04
CY2022 maia Class Of Warrants Weighted Average Remaining Contractual Term
ClassOfWarrantsWeightedAverageRemainingContractualTerm
P5Y1M28D
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
796985
CY2023Q1 maia Class Of Warrants Weighted Average Exercise Price
ClassOfWarrantsWeightedAverageExercisePrice
6.04
CY2023Q1 maia Class Of Warrants Weighted Average Remaining Contractual Term
ClassOfWarrantsWeightedAverageRemainingContractualTerm
P4Y10M28D
CY2023Q1 maia Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Percentage Of Shares Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted
0.10
CY2023Q1 maia Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price Percentage
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage
1.10
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M25D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
8907071
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5676837
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.29
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y4M20D
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
8591943
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
537522
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
713330
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0

Files In Submission

Name View Source Status
maia-20230331_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
maia-20230331_cal.xml Edgar Link unprocessable
0000950170-23-018480-index-headers.html Edgar Link pending
0000950170-23-018480-index.html Edgar Link pending
0000950170-23-018480.txt Edgar Link pending
0000950170-23-018480-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
maia-20230331.htm Edgar Link pending
maia-20230331.xsd Edgar Link pending
maia-ex31_1.htm Edgar Link pending
maia-ex31_2.htm Edgar Link pending
maia-ex32_1.htm Edgar Link pending
maia-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
maia-20230331_lab.xml Edgar Link unprocessable
maia-20230331_pre.xml Edgar Link unprocessable
maia-20230331_htm.xml Edgar Link completed